IMS 2025 | A MAIC of linvoseltamab versus ide-cel and cilta-cel in triple-class-exposed RRMM

At this year’s 2025 IMS meeting, we presented analysis of a matched-adjusted indirect comparison of linvoseltamab compared with idecabtagene vicleucel and ciltacabtagene autoleucel, which are two approved BCMA CAR-T products. So just as a brief background, linvoseltamab is a BCMA bispecific antibody that was recently approved for the treatment of triple-class-exposed relapsed/refractory multiple myeloma in patients with at least three prior lines of therapy in the European Union, at least four prior lines of therapy in the United States. And while we do have several BCMA-targeted options for the treatment of relapsed/refractory multiple myeloma, there exists no head-to-head comparison between these agents that currently exist. So in the absence of these head-to-head trials comparing these approaches, a match-adjusted indirect comparison is a standard methodology to compare outcomes between clinical trials while adjusting for baseline patient characteristics. So in this analysis, patient-level data from the pivotal LINKER-MM1 study with linvoseltamab, as well as aggregated data from the KarMMa-1 study with ide-cel and aggregate data from the CARTITUDE-1 study with cilta-cel, were used for this particular analysis. And in summary, what the outcome showed was that in this MAIC analysis, when comparing linvoseltamab with ide-cel, the complete response rate or better, the duration of response, and the progression-free survival was significantly higher with linvoseltamab compared to ide-cel, and the overall survival was numerically higher with linvoseltamab compared to ide-cel. When looking at the MAIC comparing linvoseltamab with cilta-cel, the duration of response was significantly higher with Limbrelizumab. The progression-free survival was similar between linvoseltamab and cilta-cel, while the overall survival was numerically lower with linvoseltamab compared to cilta-cel. So taken together, what this really analysis I think shows is that linvoseltamab may provide a clinically meaningful alternative in an off-the-shelf approach compared to some of the CAR-T approaches that we currently have for the treatment of relapsed/refractory multiple myeloma.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.